Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 5/20 | 0.66 |
| ▸ | PRNP | P04156 | 5/20 | 0.56 |
| ▸ | GALR3 | O60755 | 2/20 | 0.51 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15720398 | 0.84 | TRPA1 (0.64) | TRPA1PRNPPSMD14 | |
| SCHEMBL15720498 | 0.82 | TRPA1 (0.64) | TRPA1PRNPPSMD14MAPTNR1H4 | |
| SCHEMBL15720415 | 0.79 | TRPA1 (1.00) | TRPA1PRNPGALR3MAPTKMT2A | |
| SCHEMBL15720555 | 0.67 | TRPA1 (0.64) | TRPA1PRNPPSMD14KMT2ANR1H4 | |
| SCHEMBL15720399 | 0.63 | TRPA1 (1.00) | TRPA1MAPTKMT2A | |
| SCHEMBL15720499 | 0.61 | TRPA1 (1.00) | TRPA1MAPTKMT2ANR1H4 | |
| SCHEMBL15739987 | 0.61 | TRPA1 (1.00) | TRPA1PRNPPSMD14MAPTSMN1; SMN2 | |
| SCHEMBL16052459 | 0.61 | PABPC1 (0.49) | TRPA1PRNPGALR3PABPC1RAD52 | |
| SCHEMBL2937746 | 0.61 | AKT1 (0.49) | — | |
| Hydrochloric Acid SCHEMBL17785051 | 0.60 | TRPV1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394304-B2 | Imidazopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-07-19 | — | — | US | claimed |
| EP-2920169-A1 | IMIDAZOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-09-23 | — | — | EP | claimed |
| US-20150246918-A1 | IMIDAZOPYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | claimed |
| WO-2014076021-A1 | IMIDAZOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-22 | — | — | WO | claimed |
| US-9394304-B2 | Imidazopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2920169-A1 | IMIDAZOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-20150246918-A1 | IMIDAZOPYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2014076021-A1 | IMIDAZOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246918-A1 | IMIDAZOPYRIDINE DERIVATIVES | QDPR, ADRB3, HRH4 | TRPA1 882/4885PRNP 2166/4885GALR3 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.